CTSO Share Price Performance
US$0.37
-0.54 (-59.34%)
87.1% undervalued intrinsic discount
US$2.88
Fair Value
Price US$0.37
AnalystConsensusTarget US$2.88
AnalystHighTarget US$5.00
AnalystLowTarget US$0.75
Fair ValueUS$2.88
Share Pricen/a
Cytosorbents Corporation Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 10 Fair Values set on narratives written by author
CTSO Community Narratives
AN
Fair Value
·Fair Value US$2.88 87.1% undervalued intrinsic discount
FDA And Health Canada Approval Will Spur ICU Solutions
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
Fair Value
·Fair Value US$5 92.6% undervalued intrinsic discount
Aging Population And Rising ICU Demand Will Boost Adoption
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value
·Fair Value US$0.75 50.7% undervalued intrinsic discount
Healthcare Pricing And Regulation Will Stunt Prospects Despite Slight Hope
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Aging Population And Rising ICU Demand Will Boost Adoption
A small medical device maker is betting its blood-filtering treatment becomes part of routine care in intensive care units as hospitals see more critically ill patients. The upside hinges on wider doctor adoption and new approvals, but setbacks with regulators and ongoing losses could slow or derail the story.Read more
AN
US$5
92.6% undervalued intrinsic discount
Fair Value
Profit Margin
11.48%
Future PE
66.04x
Price in 2029
US$6.5
FDA And Health Canada Approval Will Spur ICU Solutions
Cytosorbents is betting that hospitals will increasingly use its blood-cleaning devices to help very sick ICU patients, especially as clinical support and cost-saving pressure grows. The big swing factor is whether regulators in the US and Canada clear a key product, which could open new markets but also exposes the company to more delays and cash strain if approvals don’t come through.Read more
AN
US$2.88
87.1% undervalued intrinsic discount
Fair Value
Profit Margin
9.91%
Future PE
45.1x
Price in 2029
US$3.72
Healthcare Pricing And Regulation Will Stunt Prospects Despite Slight Hope
Cytosorbents faces a tough road as hospitals and insurers push harder to cut costs, while care shifts away from intensive hospital treatments that its core product depends on. The upside hinges on wider clinical use and a potential green light from regulators that could open new markets—if those approvals finally come through.Read more
AN
US$0.75
50.7% undervalued intrinsic discount
Fair Value
Profit Margin
12.19%
Future PE
9.15x
Price in 2029
US$0.97
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
CTSO: Nasdaq Extension And Clinical Data Will Support Future Upside Potential
Fair Value: US$5 92.6% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
CTSO: Nasdaq Compliance Extension Will Support Future Turnaround Potential
Fair Value: US$2.88 87.1% undervalued intrinsic discount
6 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
CTSO: ICU Utilization And Nasdaq Compliance Extension Will Support Future Upside
Fair Value: US$0.75 50.7% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Cytosorbents Corporation Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 06, 2026
- -0.19
- 71.01%
- -31.85%
- 773.0%
About CTSO
- Founded
- 1997
- Employees
- 129
- CEO
- WebsiteView website
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications. The company also develops DrugSorb-ATR antithrombotic removal system, an investigational device to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs; ECOS-300CY to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; and PuriFi, an advanced hemoperfusion pump for blood purification therapies. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
